{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:38:17Z","timestamp":1794044297111,"version":"4.8.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["Munich site"],"award-info":[{"award-number":["Munich site"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB TRR 179"],"award-info":[{"award-number":["SFB TRR 179"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB TRR 179"],"award-info":[{"award-number":["SFB TRR 179"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002745","name":"Bayerische Forschungsstiftung","doi-asserted-by":"publisher","award":["CoVRAPID"],"award-info":[{"award-number":["CoVRAPID"]}],"id":[{"id":"10.13039\/501100002745","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002745","name":"Bayerische Forschungsstiftung","doi-asserted-by":"publisher","award":["CoVRapid"],"award-info":[{"award-number":["CoVRapid"]}],"id":[{"id":"10.13039\/501100002745","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009318","name":"Helmholtz Association","doi-asserted-by":"publisher","award":["COVIPA"],"award-info":[{"award-number":["COVIPA"]}],"id":[{"id":"10.13039\/501100009318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009318","name":"Helmholtz Association","doi-asserted-by":"publisher","award":["COVIPA"],"award-info":[{"award-number":["COVIPA"]}],"id":[{"id":"10.13039\/501100009318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008848","name":"State Ministry of Education and Culture, Science and the Arts | Elitenetzwerk Bayern","doi-asserted-by":"publisher","award":["ForCOVID"],"award-info":[{"award-number":["ForCOVID"]}],"id":[{"id":"10.13039\/501100008848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008848","name":"State Ministry of Education and Culture, Science and the Arts | Elitenetzwerk Bayern","doi-asserted-by":"publisher","award":["ForCovid"],"award-info":[{"award-number":["ForCovid"]}],"id":[{"id":"10.13039\/501100008848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Anti-viral immunity continuously declines over time after SARS-CoV-2 infection. Here, we characterize the dynamics of anti-viral immunity during long-term follow-up and after BNT162b2 mRNA-vaccination in convalescents after asymptomatic or mild SARS-CoV-2 infection. Virus-specific and virus-neutralizing antibody titers rapidly declined in convalescents over 9 months after infection, whereas virus-specific cytokine-producing polyfunctional T cells persisted, among which IL-2-producing T cells correlated with virus-neutralizing antibody titers. Among convalescents, 5% of individuals failed to mount long-lasting immunity after infection and showed a delayed response to vaccination compared to 1% of na\u00efve vaccinees, but successfully responded to prime\/boost vaccination. During the follow-up period, 8% of convalescents showed a selective increase in virus-neutralizing antibody titers without accompanying increased frequencies of circulating SARS-CoV-2-specific T cells. The same convalescents, however, responded to vaccination with simultaneous increase in antibody and T cell immunity revealing the strength of mRNA-vaccination to increase virus-specific immunity in convalescents.<\/jats:p>","DOI":"10.1038\/s41467-021-27649-y","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T06:02:59Z","timestamp":1641794579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0991-6547","authenticated-orcid":false,"given":"Nina","family":"Koerber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4982-0347","authenticated-orcid":false,"given":"Alina","family":"Priller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1524-9071","authenticated-orcid":false,"given":"Sarah","family":"Yazici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3597-4118","authenticated-orcid":false,"given":"Tanja","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho-Chin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrvoje","family":"Mijo\u010devi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-333X","authenticated-orcid":false,"given":"Hannah","family":"Wintersteller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Jeske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6560-0136","authenticated-orcid":false,"given":"Emanuel","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Feuerherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Tinnefeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0253-9056","authenticated-orcid":false,"given":"Christof","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8381-3597","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Ruland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9110-3950","authenticated-orcid":false,"given":"Markus","family":"Gerhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9723-393X","authenticated-orcid":false,"given":"Bernhard","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3950-2481","authenticated-orcid":false,"given":"Catharina","family":"Christa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Zelger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedwig","family":"Roggendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Halle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Erber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lingor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1384-8946","authenticated-orcid":false,"given":"Oliver","family":"Keppler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1393-8527","authenticated-orcid":false,"given":"Dietmar","family":"Zehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9421-1911","authenticated-orcid":false,"given":"Ulrike","family":"Protzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2983-0414","authenticated-orcid":false,"given":"Percy A.","family":"Knolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"27649_CR1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"27649_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"27649_CR3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","volume":"26","author":"KG Andersen","year":"2020","unstructured":"Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C. & Garry, R. F. The proximal origin of SARS-CoV-2. Nat. Med. 26, 450\u2013452 (2020).","journal-title":"Nat. Med."},{"key":"27649_CR4","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMcp2009249","volume":"383","author":"RT Gandhi","year":"2020","unstructured":"Gandhi, R. T., Lynch, J. B. & Del Rio, C. Mild or moderate Covid-19. The. N. Engl. J. Med. 383, 1757\u20131766 (2020).","journal-title":"N. Engl. J. Med."},{"key":"27649_CR5","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1056\/NEJMcp2009575","volume":"383","author":"DA Berlin","year":"2020","unstructured":"Berlin, D. A., Gulick, R. M. & Martinez, F. J. Severe Covid-19. N. Engl. J. Med. 383, 2451\u20132460 (2020).","journal-title":"N. Engl. J. Med."},{"key":"27649_CR6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280 e278 (2020).","journal-title":"Cell"},{"key":"27649_CR7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2598-9","volume":"587","author":"J Braun","year":"2020","unstructured":"Braun, J. et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature 587, 270\u2013274 (2020).","journal-title":"Nature"},{"key":"27649_CR8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","volume":"183","author":"T Sekine","year":"2020","unstructured":"Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183, 158\u2013168 e114 (2020).","journal-title":"Cell"},{"key":"27649_CR9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41591-020-01143-2","volume":"27","author":"I Schulien","year":"2021","unstructured":"Schulien, I. et al. Characterization of pre-existing and induced SARS-CoV-2-specific CD8(+) T cells. Nat. Med. 27, 78\u201385 (2021).","journal-title":"Nat. Med."},{"key":"27649_CR10","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.1172\/JCI140965","volume":"130","author":"A Sattler","year":"2020","unstructured":"Sattler, A. et al. SARS-CoV-2-specific T cell responses and correlations with COVID-19 patient predisposition. J. Clin. Invest. 130, 6477\u20136489 (2020).","journal-title":"J. Clin. Invest."},{"key":"27649_CR11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","volume":"584","author":"DF Robbiani","year":"2020","unstructured":"Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437\u2013442 (2020).","journal-title":"Nature"},{"key":"27649_CR12","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","volume":"26","author":"QX Long","year":"2020","unstructured":"Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845\u2013848 (2020).","journal-title":"Nat. Med."},{"key":"27649_CR13","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","volume":"371","author":"JM Dan","year":"2021","unstructured":"Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371, eabf4063 (2021).","journal-title":"Science"},{"key":"27649_CR14","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u20131501 e1415 (2020).","journal-title":"Cell"},{"key":"27649_CR15","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1126\/science.abd7728","volume":"370","author":"A Wajnberg","year":"2020","unstructured":"Wajnberg, A. et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 370, 1227\u20131230 (2020).","journal-title":"Science"},{"key":"27649_CR16","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","volume":"21","author":"Y Peng","year":"2020","unstructured":"Peng, Y. et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 21, 1336\u20131345 (2020).","journal-title":"Nat. Immunol."},{"key":"27649_CR17","volume":"12","author":"J Wu","year":"2021","unstructured":"Wu, J. et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Nat. Commun. 12, 1813 (2021).","journal-title":"Nat. Commun."},{"key":"27649_CR18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-021-03647-4","volume":"595","author":"JS Turner","year":"2021","unstructured":"Turner, J. S. et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature 595, 421\u2013425 (2021).","journal-title":"Nature"},{"key":"27649_CR19","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-021-03696-9","volume":"595","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 595, 426\u2013431 (2021).","journal-title":"Nature"},{"key":"27649_CR20","doi-asserted-by":"crossref","first-page":"e20202515","DOI":"10.1084\/jem.20202515","volume":"218","author":"G Breton","year":"2021","unstructured":"Breton, G. et al. Persistent cellular immunity to SARS-CoV-2 infection. J. Exp. Med. 218, e20202515 (2021).","journal-title":"J. Exp. Med."},{"key":"27649_CR21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2020.11.029","volume":"184","author":"LB Rodda","year":"2021","unstructured":"Rodda, L. B. et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell 184, 169\u2013183 e117 (2021).","journal-title":"Cell"},{"key":"27649_CR22","doi-asserted-by":"crossref","first-page":"eabi6950","DOI":"10.1126\/sciimmunol.abi6950","volume":"6","author":"RR Goel","year":"2021","unstructured":"Goel, R. R. et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination. Sci. Immunol. 6, eabi6950 (2021).","journal-title":"Sci. Immunol."},{"key":"27649_CR23","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1056\/NEJMoa2026116","volume":"383","author":"DF Gudbjartsson","year":"2020","unstructured":"Gudbjartsson, D. F. et al. Humoral immune response to SARS-CoV-2 in iceland. N. Engl. J. Med. 383, 1724\u20131734 (2020).","journal-title":"N. Engl. J. Med."},{"key":"27649_CR24","doi-asserted-by":"crossref","first-page":"eabf8891","DOI":"10.1126\/sciimmunol.abf8891","volume":"5","author":"GE Hartley","year":"2020","unstructured":"Hartley, G. E. et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci. Immunol. 5, eabf8891 (2020).","journal-title":"Sci. Immunol."},{"key":"27649_CR25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115\u2013119 (2020).","journal-title":"Nature"},{"key":"27649_CR26","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","volume":"52","author":"L Ni","year":"2020","unstructured":"Ni, L. et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 52, 971\u2013977 e973 (2020).","journal-title":"Immunity"},{"key":"27649_CR27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41577-021-00550-x","volume":"21","author":"D Cromer","year":"2021","unstructured":"Cromer, D. et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat. Rev. Immunol. 21, 395\u2013404 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"27649_CR28","doi-asserted-by":"crossref","first-page":"e20210583","DOI":"10.1084\/jem.20210583","volume":"218","author":"NR Cheemarla","year":"2021","unstructured":"Cheemarla, N. R. et al. Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics. J. Exp. Med. 218, e20210583 (2021).","journal-title":"J. Exp. Med."},{"key":"27649_CR29","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","volume":"27","author":"A Park","year":"2020","unstructured":"Park, A. & Iwasaki, A. Type I and type III interferons\u2014induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe 27, 870\u2013878 (2020).","journal-title":"Cell Host Microbe"},{"key":"27649_CR30","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cell.2021.02.029","volume":"184","author":"JL Schultze","year":"2021","unstructured":"Schultze, J. L. & Aschenbrenner, A. C. COVID-19 and the human innate immune system. Cell 184, 1671\u20131692 (2021).","journal-title":"Cell"},{"key":"27649_CR31","doi-asserted-by":"crossref","unstructured":"Credle, J. J. et al. Neutralizing IFNL3 autoantibodies in severe COVID-19 identified using molecular indexing of proteins by self-assembly. bioRxiv (2021).","DOI":"10.1101\/2021.03.02.432977"},{"key":"27649_CR32","doi-asserted-by":"crossref","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","volume":"370","author":"P Bastard","year":"2020","unstructured":"Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020).","journal-title":"Science"},{"key":"27649_CR33","doi-asserted-by":"crossref","first-page":"e3001158","DOI":"10.1371\/journal.pbio.3001158","volume":"19","author":"P Kovski","year":"2021","unstructured":"Kovski, P. et al. Disparate temperature-dependent virus-host dynamics for SARS-CoV-2 and SARS-CoV in the human respiratory epithelium. PLoS Biol. 19, e3001158 (2021).","journal-title":"PLoS Biol."},{"key":"27649_CR34","doi-asserted-by":"publisher","unstructured":"Loske, J. et al. Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. Nat. Biotechnol. (2021) https:\/\/doi.org\/10.1038\/s41587-021-01037-9.","DOI":"10.1038\/s41587-021-01037-9"},{"key":"27649_CR35","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","volume":"20","author":"MZ Tay","year":"2020","unstructured":"Tay, M. Z., Poh, C. M., Renia, L., MacAry, P. A. & Ng, L. F. P. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol. 20, 363\u2013374 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"27649_CR36","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.cell.2020.10.001","volume":"183","author":"BJ Meckiff","year":"2020","unstructured":"Meckiff, B. J. et al. Imbalance of regulatory and cytotoxic SARS-CoV-2-Reactive CD4(+) T cells in COVID-19. Cell 183, 1340\u20131353 e1316 (2020).","journal-title":"Cell"},{"key":"27649_CR37","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","volume":"183","author":"C Rydyznski Moderbacher","year":"2020","unstructured":"Rydyznski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996\u20131012 e1019 (2020).","journal-title":"Cell"},{"key":"27649_CR38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41581-020-00357-4","volume":"17","author":"L Perico","year":"2021","unstructured":"Perico, L. et al. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat. Rev. Nephrol. 17, 46\u201364 (2021).","journal-title":"Nat. Rev. Nephrol."},{"key":"27649_CR39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41577-021-00536-9","volume":"21","author":"A Bonaventura","year":"2021","unstructured":"Bonaventura, A. et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat. Rev. Immunol. 21, 319\u2013329 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"27649_CR40","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","volume":"584","author":"C Lucas","year":"2020","unstructured":"Lucas, C. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463\u2013469 (2020).","journal-title":"Nature"},{"key":"27649_CR41","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","volume":"586","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 586, 594\u2013599 (2020).","journal-title":"Nature"},{"key":"27649_CR42","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567\u2013571 (2020).","journal-title":"Nature"},{"key":"27649_CR43","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2020","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2020).","journal-title":"N. Engl. J. Med."},{"key":"27649_CR44","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187\u20132201 (2021).","journal-title":"N. Engl. J. Med."},{"key":"27649_CR45","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan, N. et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384, 1412\u20131423 (2021).","journal-title":"N. Engl. J. Med."},{"key":"27649_CR46","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2\u2014preliminary report. N. Engl. J. Med. 383, 1920\u20131931 (2020).","journal-title":"N. Engl. J. Med."},{"key":"27649_CR47","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMc2101667","volume":"384","author":"F Krammer","year":"2021","unstructured":"Krammer, F. et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N. Engl. J. Med. 384, 1372\u20131374 (2021).","journal-title":"N. Engl. J. Med."},{"key":"27649_CR48","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","volume":"584","author":"N Le Bert","year":"2020","unstructured":"Le Bert, N. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584, 457\u2013462 (2020).","journal-title":"Nature"},{"key":"27649_CR49","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22958-8","volume":"12","author":"S Dispinseri","year":"2021","unstructured":"Dispinseri, S. et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat. Commun. 12, 2670 (2021).","journal-title":"Nat. Commun."},{"key":"27649_CR50","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41577-020-0308-3","volume":"20","author":"X Cao","year":"2020","unstructured":"Cao, X. COVID-19: immunopathology and its implications for therapy. Nat. Rev. Immunol. 20, 269\u2013270 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"27649_CR51","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"27649_CR52","doi-asserted-by":"crossref","first-page":"eabe0367","DOI":"10.1126\/sciimmunol.abe0367","volume":"5","author":"AS Iyer","year":"2020","unstructured":"Iyer, A. S. et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci. Immunol. 5, eabe0367 (2020).","journal-title":"Sci. Immunol."},{"key":"27649_CR53","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","volume":"5","author":"J Seow","year":"2020","unstructured":"Seow, J. et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat. Microbiol. 5, 1598\u20131607 (2020).","journal-title":"Nat. Microbiol."},{"key":"27649_CR54","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","volume":"591","author":"C Gaebler","year":"2021","unstructured":"Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639\u2013644 (2021).","journal-title":"Nature"},{"key":"27649_CR55","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.cell.2021.01.050","volume":"184","author":"A Sokal","year":"2021","unstructured":"Sokal, A. et al. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell 184, 1201\u20131213 e1214 (2021).","journal-title":"Cell"},{"key":"27649_CR56","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri2274","volume":"8","author":"RA Seder","year":"2008","unstructured":"Seder, R. A., Darrah, P. A. & Roederer, M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8, 247\u2013258 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"27649_CR57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0022-1759(01)00535-X","volume":"260","author":"JR Currier","year":"2002","unstructured":"Currier, J. R. et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Methods 260, 157\u2013172 (2002).","journal-title":"J. Immunol. Methods"},{"key":"27649_CR58","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.abd3871","volume":"370","author":"J Mateus","year":"2020","unstructured":"Mateus, J. et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science 370, 89\u201394 (2020).","journal-title":"Science"},{"key":"27649_CR59","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","volume":"22","author":"A Nelde","year":"2021","unstructured":"Nelde, A. et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat. Immunol. 22, 74\u201385 (2021).","journal-title":"Nat. Immunol."},{"key":"27649_CR60","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.3390\/v4112636","volume":"4","author":"W Zhang","year":"2012","unstructured":"Zhang, W., Moldovan, I., Targoni, O. S., Subbramanian, R. A. & Lehmann, P. V. How much of virus-specific CD8 T cell reactivity is detected with a peptide pool when compared to individual peptides? Viruses 4, 2636\u20132649 (2012).","journal-title":"Viruses"},{"key":"27649_CR61","doi-asserted-by":"crossref","first-page":"eabf3698","DOI":"10.1126\/sciimmunol.abf3698","volume":"5","author":"CJ Reynolds","year":"2020","unstructured":"Reynolds, C. J. et al. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci. Immunol. 5, eabf3698 (2020).","journal-title":"Sci. Immunol."},{"key":"27649_CR62","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.immuni.2021.01.008","volume":"54","author":"A Bonifacius","year":"2021","unstructured":"Bonifacius, A. et al. COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity 54, 340\u2013354 e346 (2021).","journal-title":"Immunity"},{"key":"27649_CR63","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S2666-5247(21)00025-2","volume":"2","author":"WN Chia","year":"2021","unstructured":"Chia, W. N. et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe 2, e240\u2013e249 (2021).","journal-title":"Lancet Microbe"},{"key":"27649_CR64","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(21)00502-X","volume":"397","author":"M Prendecki","year":"2021","unstructured":"Prendecki, M. et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet 397, 1178\u20131181 (2021).","journal-title":"Lancet"},{"key":"27649_CR65","first-page":"eabh1282","volume":"30","author":"CJ Reynolds","year":"2021","unstructured":"Reynolds, C. J. et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science. 30, eabh1282 (2021).","journal-title":"Science"},{"key":"27649_CR66","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-021-03841-4","volume":"597","author":"V Oberhardt","year":"2021","unstructured":"Oberhardt, V. et al. Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine. Nature. 597, 268\u2013273 (2021).","journal-title":"Nature"},{"key":"27649_CR67","doi-asserted-by":"crossref","first-page":"109570","DOI":"10.1016\/j.celrep.2021.109570","volume":"36","author":"D Lozano-Ojalvo","year":"2021","unstructured":"Lozano-Ojalvo, D. et al. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals. Cell Rep. 36, 109570 (2021).","journal-title":"Cell Rep."},{"key":"27649_CR68","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41591-021-01325-6","volume":"27","author":"JE Ebinger","year":"2021","unstructured":"Ebinger, J. E. et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat. Med. 27, 981\u2013984 (2021).","journal-title":"Nat. Med."},{"key":"27649_CR69","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.immuni.2020.10.006","volume":"53","author":"AP Ferretti","year":"2020","unstructured":"Ferretti, A. P. et al. Unbiased screens show CD8(+) T cells of COVID-19 patients recognize shared epitopes in SARS-CoV-2 that largely reside outside the spike protein. Immunity 53, 1095\u20131107 e1093 (2020).","journal-title":"Immunity"},{"key":"27649_CR70","doi-asserted-by":"crossref","first-page":"e1009842","DOI":"10.1371\/journal.ppat.1009842","volume":"17","author":"J Heide","year":"2021","unstructured":"Heide, J. et al. Broadly directed SARS-CoV-2-specific CD4+ T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19. PLoS Pathog. 17, e1009842 (2021).","journal-title":"PLoS Pathog."},{"key":"27649_CR71","volume":"12","author":"AK Wheatley","year":"2021","unstructured":"Wheatley, A. K. et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat. Commun. 12, 1162 (2021).","journal-title":"Nat. Commun."},{"key":"27649_CR72","doi-asserted-by":"crossref","first-page":"24384","DOI":"10.1073\/pnas.2015486117","volume":"117","author":"JR Habel","year":"2020","unstructured":"Habel, J. R. et al. Suboptimal SARS-CoV-2-specific CD8(+) T cell response associated with the prominent HLA-A*02:01 phenotype. Proc. Natl Acad. Sci. USA 117, 24384\u201324391 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"27649_CR73","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1056\/NEJMc2025179","volume":"383","author":"FJ Ibarrondo","year":"2020","unstructured":"Ibarrondo, F. J. et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N. Engl. J. Med. 383, 1085\u20131087 (2020).","journal-title":"N. Engl. J. Med."},{"key":"27649_CR74","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/infdis\/jiaa618","volume":"223","author":"KHD Crawford","year":"2021","unstructured":"Crawford, K. H. D. et al. Dynamics of neutralizing antibody titers in the months after severe acute respiratory syndrome coronavirus 2 infection. J. Infect. Dis. 223, 197\u2013205 (2021).","journal-title":"J. Infect. Dis."},{"key":"27649_CR75","doi-asserted-by":"crossref","first-page":"e02590-20","DOI":"10.1128\/mBio.02590-20","volume":"11","author":"G Beaudoin-Bussieres","year":"2020","unstructured":"Beaudoin-Bussieres, G. et al. Decline of humoral responses against SARS-CoV-2 spike in convalescent individuals. mBio 11, e02590-20 (2020).","journal-title":"mBio"},{"key":"27649_CR76","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1001\/jama.2021.7212","volume":"325","author":"J Abbasi","year":"2021","unstructured":"Abbasi, J. Researchers tie severe immunosuppression to chronic COVID-19 and virus variants. J. Am. Med. Assoc. 325, 2033\u20132035 (2021).","journal-title":"J. Am. Med. Assoc."},{"key":"27649_CR77","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1056\/NEJMsb2104756","volume":"385","author":"L Corey","year":"2021","unstructured":"Corey, L. et al. SARS-CoV-2 variants in patients with immunosuppression. N. Engl. J. Med. 385, 562\u2013566 (2021).","journal-title":"N. Engl. J. Med."},{"key":"27649_CR78","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMc2031364","volume":"383","author":"B Choi","year":"2020","unstructured":"Choi, B. et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N. Engl. J. Med. 383, 2291\u20132293 (2020).","journal-title":"N. Engl. J. Med."},{"key":"27649_CR79","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41586-021-03901-9","volume":"597","author":"AK Keita","year":"2021","unstructured":"Keita, A. K. et al. Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks. Nature 597, 539\u2013543 (2021).","journal-title":"Nature"},{"key":"27649_CR80","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41593-020-00758-5","volume":"24","author":"J Meinhardt","year":"2021","unstructured":"Meinhardt, J. et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat. Neurosci. 24, 168\u2013175 (2021).","journal-title":"Nat. Neurosci."},{"key":"27649_CR81","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41590-018-0260-6","volume":"20","author":"SR Allie","year":"2019","unstructured":"Allie, S. R. et al. The establishment of resident memory B cells in the lung requires local antigen encounter. Nat. Immunol. 20, 97\u2013108 (2019).","journal-title":"Nat. Immunol."},{"key":"27649_CR82","doi-asserted-by":"crossref","first-page":"eaam6970","DOI":"10.1126\/sciimmunol.aam6970","volume":"2","author":"A Pizzolla","year":"2017","unstructured":"Pizzolla, A. et al. Resident memory CD8(+) T cells in the upper respiratory tract prevent pulmonary influenza virus infection. Sci. Immunol. 2, eaam6970 (2017).","journal-title":"Sci. Immunol."},{"key":"27649_CR83","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.coi.2019.05.011","volume":"59","author":"ME Snyder","year":"2019","unstructured":"Snyder, M. E. & Farber, D. L. Human lung tissue resident memory T cells in health and disease. Curr. Opin. Immunol. 59, 101\u2013108 (2019).","journal-title":"Curr. Opin. Immunol."},{"key":"27649_CR84","first-page":"103.101","volume":"206","author":"IEM Uddback","year":"2021","unstructured":"Uddback, I. E. M. et al. Resident Memory CD8+ T cells in the respiratory tract prevent transmission of respiratory viruses. J. Immunol. 206, 103.101\u2013103.101 (2021).","journal-title":"J. Immunol."},{"key":"27649_CR85","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23333-3","volume":"12","author":"J Grau-Exposito","year":"2021","unstructured":"Grau-Exposito, J. et al. Peripheral and lung resident memory T cell responses against SARS-CoV-2. Nat. Commun. 12, 3010 (2021).","journal-title":"Nat. Commun."},{"key":"27649_CR86","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/d41586-021-01396-y","volume":"593","author":"DL Farber","year":"2021","unstructured":"Farber, D. L. Tissues, not blood, are where immune cells function. Nature 593, 506\u2013509 (2021).","journal-title":"Nature"},{"key":"27649_CR87","doi-asserted-by":"publisher","unstructured":"Gazit, S. et al. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.08.24.21262415 (2021).","DOI":"10.1101\/2021.08.24.21262415"},{"key":"27649_CR88","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1056\/NEJMoa2105000","volume":"384","author":"E Hacisuleyman","year":"2021","unstructured":"Hacisuleyman, E. et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N. Engl. J. Med. 384, 2212\u20132218 (2021).","journal-title":"N. Engl. J. Med."},{"key":"27649_CR89","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1001\/jama.2021.7152","volume":"325","author":"Y Angel","year":"2021","unstructured":"Angel, Y. et al. Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. J. Am. Med. Assoc. 325, 2457\u20132465 (2021).","journal-title":"J. Am. Med. Assoc."},{"key":"27649_CR90","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","volume":"397","author":"EJ Haas","year":"2021","unstructured":"Haas, E. J. et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 397, 1819\u20131829 (2021).","journal-title":"Lancet"},{"key":"27649_CR91","doi-asserted-by":"crossref","first-page":"6032","DOI":"10.1038\/s41467-021-26154-6","volume":"12","author":"F Rovida","year":"2021","unstructured":"Rovida, F. et al. SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers. Nat Commun. 12, 6032 (2021).","journal-title":"Nat Commun"},{"key":"27649_CR92","doi-asserted-by":"crossref","first-page":"e02596-20","DOI":"10.1128\/JCM.02596-20","volume":"59","author":"LH Harritshoj","year":"2021","unstructured":"Harritshoj, L. H. et al. Comparison of 16 serological SARS-CoV-2 immunoassays in 16 clinical laboratories. J. Clin. Microbiol. 59, e02596-20 (2021).","journal-title":"J. Clin. Microbiol."},{"key":"27649_CR93","doi-asserted-by":"crossref","first-page":"620222","DOI":"10.3389\/fpubh.2020.620222","volume":"8","author":"A Chiereghin","year":"2020","unstructured":"Chiereghin, A. et al. Recent advances in the evaluation of serological assays for the diagnosis of SARS-CoV-2 infection and COVID-19. Front. Public Health 8, 620222 (2020).","journal-title":"Front. Public Health"},{"key":"27649_CR94","doi-asserted-by":"crossref","first-page":"e01694-20","DOI":"10.1128\/JCM.01694-20","volume":"58","author":"P Muench","year":"2020","unstructured":"Muench, P. et al. Development and validation of the elecsys anti-SARS-CoV-2 Immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2. J. Clin. Microbiol. 58, e01694-20 (2020).","journal-title":"J. Clin. Microbiol."},{"key":"27649_CR95","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S1473-3099(20)30634-4","volume":"20","author":"National S-C-SAEG.","year":"2020","unstructured":"National S-C-SAEG. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect. Dis. 20, 1390\u20131400 (2020).","journal-title":"Lancet Infect. Dis."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27649-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27649-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27649-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T10:35:08Z","timestamp":1669286108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27649-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["27649"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-27649-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-677167\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"6 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}